BCL2L11 and neoplasm: The combination of aspirin and osimertinib inhibited AKT/FOXO3a signaling component phosphorylation and increased Bim expression in osimertinib-resistant NSCLC cells and promoted Bim-dependent apoptosis, which decreased tumor growth in vivo (Han et al., 2020).